The glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, inhibits small intestinal motility, flow, transit and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomised controlled trial.

Diabetes ◽

10.2337/db15-0893 ◽

2015 ◽

pp. db150893 ◽

Cited By ~ 7

Author(s):

Sony S. Thazhath ◽

Chinmay S. Marathe ◽

Tongzhi Wu ◽

Jessica Chang ◽

Joan Khoo ◽

...

Keyword(s):

Type 2 Diabetes ◽

Healthy Subjects ◽

Receptor Agonist ◽

Controlled Trial ◽

Small Intestinal Motility ◽

Glucagon Like Peptide ◽

Small Intestinal ◽

Glucagon Like Peptide 1 ◽

Randomised Controlled

Download Full-text

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled

Diabetes Obesity and Metabolism ◽

10.1111/dom.12382 ◽

2014 ◽

Vol 16 (12) ◽

pp. 1257-1264 ◽

Cited By ~ 62

Author(s):

J. Reusch ◽

M. W. Stewart ◽

C. M. Perkins ◽

D. T. Cirkel ◽

J. Ye ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Metabolic improvement with short‐term glucagon like peptide‐1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients type 2 diabetes: a randomized double‐blind placebo‐controlled trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14480 ◽

2021 ◽

Author(s):

Annemie Stege Bojer ◽

Martin Heyn Sørensen ◽

Jenny Bjerre ◽

Peter Gæde ◽

Niels Vejlstrup ◽

...

Keyword(s):

Type 2 Diabetes ◽

Diastolic Dysfunction ◽

Receptor Agonist ◽

Controlled Trial ◽

Short Term ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Population Pharmacokinetics of Lixisenatide, a Once- Daily Human Glucagon-Like Peptide-1 Receptor Agonist, in Healthy Subjects and in Patients with Type 2 Diabetes

Journal of Pharmaceutics & Drug Delivery Research ◽

10.4172/2325-9604.1000112 ◽

2013 ◽

Vol 02 (01) ◽

Cited By ~ 3

Keyword(s):

Type 2 Diabetes ◽

Population Pharmacokinetics ◽

Healthy Subjects ◽

Receptor Agonist ◽

Once Daily ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial

Journal of Dermatological Treatment ◽

10.1080/09546634.2020.1826392 ◽

2020 ◽

pp. 1-7

Author(s):

Lu Lin ◽

Xiangjin Xu ◽

Yunjie Yu ◽

Hongjiang Ye ◽

Xiaoqiong He ◽

...

Keyword(s):

Type 2 Diabetes ◽

Randomized Controlled Trial ◽

Receptor Agonist ◽

Controlled Trial ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes

Diabetes Obesity and Metabolism ◽

10.1111/dom.12802 ◽

2016 ◽

Vol 19 (2) ◽

pp. 200-207 ◽

Cited By ~ 17

Author(s):

Michael A. Nauck ◽

Melanie Kahle ◽

Oleg Baranov ◽

Carolyn F. Deacon ◽

Jens J. Holst

Keyword(s):

Type 2 Diabetes ◽

Randomized Controlled Trial ◽

Receptor Agonist ◽

Controlled Trial ◽

Dipeptidyl Peptidase 4 ◽

Randomized Controlled ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients

Diabetes ◽

10.2337/db18-2231-pub ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 2231-PUB

Author(s):

SASAN FAZELI ◽

NICOLE EHRHARDT

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Receptor Agonist ◽

Premixed Insulin ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

938-P: The Relationship between Timing of Initiation on a Glucagon-Like Peptide-1 Receptor Agonist and HbA1c among Patients with Type 2 Diabetes

Diabetes ◽

10.2337/db20-938-p ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 938-P

Author(s):

RALEIGH E. MALIK ◽

REEMA MODY ◽

MAUREEN J. LAGE ◽

KRISTINA BOYE

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Timing Of Initiation ◽

The Relationship

Download Full-text

Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies

Diabetes Therapy ◽

10.1007/s13300-021-01021-1 ◽

2021 ◽

Author(s):

Thomas M. Caparrotta ◽

Jack B. Templeton ◽

Thomas A. Clay ◽

Sarah H. Wild ◽

Rebecca M. Reynolds ◽

...

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Observational Studies ◽

Receptor Agonist ◽

Population Based ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?

Clinical Diabetes ◽

10.2337/cd17-0065 ◽

2018 ◽

Vol 36 (2) ◽

pp. 138-147 ◽

Cited By ~ 4

Author(s):

Vanita R. Aroda ◽

Joseph R. Arulandu ◽

Anthony J. Cannon

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Receptor Agonist ◽

Two Agents ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Better Than

Download Full-text

4324Effects of the glucagon like peptide-1 receptor agonist on arterial stiffness, LV myocardial deformation and oxidative stress in newly diagnosed type 2 diabetes after 6-month treatment

European Heart Journal ◽

10.1093/eurheartj/ehy563.4324 ◽

2018 ◽

Vol 39 (suppl_1) ◽

Author(s):

I Ikonomidis ◽

G Pavlidis ◽

V Lambadiari ◽

F Kousathana ◽

H Triantafyllidi ◽

...

Keyword(s):

Oxidative Stress ◽

Type 2 Diabetes ◽

Arterial Stiffness ◽

Receptor Agonist ◽

Myocardial Deformation ◽

Newly Diagnosed ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

And Oxidative Stress

Download Full-text